Background: Data regarding the clinical outcomes in patients with atrial fibrillation (AF)
receiving dual antiplatelet therapy (DAPT) and an anticoagulant in addition to DAPT (DAPT+ …

Background The optimal antithrombotic regimen in patients with atrial fibrillation (AF)
undergoing drug-eluting stent (DES) implantation for complex coronary artery disease is …

Background The optimal antithrombotic therapy for atrial fibrillation (AF) patients undergoing
coronary stenting is unknown. The present meta-analysis sought to investigate the efficacy …

Background Oral anticoagulation (OAC) is the recommended therapy for patients with atrial
fibrillation (AF) because it reduces the risk of stroke and other thromboembolic events. Dual …

The coexistence of atrial fibrillation and coronary artery disease is commonly found in
clinical practice. The aim of this meta-analysis is to compare the clinical efficacy and safety …

Background and objective Most Asian patients with atrial fibrillation (AF) who undergo
percutaneous coronary intervention (PCI) receive only dual antiplatelet therapy (DAPT) …

Background Chronic atrial fibrillation (AF), coexisting with a history of recent coronary
angioplasty with stent (PCI-S), represents an encoded indication for oral anticoagulation …

There are limited data regarding the use of antithrombotic therapy in patients with atrial
fibrillation (AF) who underwent percutaneous coronary intervention (PCI) with drug-eluting …

A challenge for antithrombotic treatment is patients who present with atrial fibrillation (AF)
and acute coronary syndrome, particularly in patients who have undergone coronary …

Background The safety and efficacy of triple therapy (TT; warfarin with dual antiplatelet
therapy [DAPT]) in post–percutaneous coronary intervention (PCI) patients with atrial …